Virpax Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States (ticker: VRPX). Headquartered in Berwyn, Pennsylvania, the company was established and began operations in 2017. Virpax is still a preclinical-stage business with a limited operating history, which places it in the high-risk, development-stage segment of healthcare investing. Its valuation narrative depends heavily on scientific validation, regulatory progress, and access to capital rather than on current product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708331/000173112225000316/e6385_10k.htm?utm_source=openai)) Virpax’s core business is the development of proprietary drug-delivery systems and formulations aimed primarily at non-opioid pain management and certain central nervous system (CNS) disorders. The company highlights its Molecular Envelope Technology (MET) platform, which is designed to improve intranasal delivery and optimize how active ingredients reach their intended targets. Its pipeline includes Probudur for postoperative pain, Epoladerm for knee osteoarthritis, Envelta for severe pain, AnQlar as a potential antiviral barrier, and NobrXiol for select rare pediatric epilepsy indications. In practical terms, Virpax is a platform-driven pipeline company whose value proposition is built around differentiated delivery technology and unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1708331/000173112225000316/e6385_10k.htm?utm_source=openai)) From a competitive standpoint, Virpax operates in crowded therapeutic areas where large pharmaceutical companies, specialty biotechs, and generic drug-delivery developers compete for clinical data, intellectual property, and regulatory traction. Virpax attempts to stand out through non-addictive treatment concepts, novel formulations, and targeted routes of administration. The company has also referenced cooperative research and development agreements with U.S. government organizations, including the NIH and the Department of Defense, which can support development credibility and scientific collaboration. However, these arrangements do not eliminate the usual biotech risks tied to trial execution, FDA review, and financing. ([virpaxpharma.com](https://virpaxpharma.com/2024/05/13/virpax-pharmaceuticals-reports-2024-first-quarter-results-and-recent-developments/?utm_source=openai)) Geographically, Virpax’s operations are centered in the United States, with its corporate headquarters in Berwyn, Pennsylvania. Recent notable items include 2024 operating updates, financing announcements, and a reverse stock split disclosed in March 2025, all of which underscore the company’s ongoing capital-markets dependence. For investors in France, Belgium, and Switzerland, Virpax should be viewed as a speculative micro-cap biotech with an early-stage pipeline, a potentially differentiated technology stack, and a binary investment profile driven by development milestones, regulatory outcomes, and balance-sheet management. ([virpaxpharma.com](https://virpaxpharma.com/contact/?utm_source=openai))